跳到正文
BioPharm International·· 11 天前AI 评分32

ProBio将肿瘤抗体授权给AbTis用于位点特异性ADC开发

ProBio Licenses Oncology Antibody to AbTis for Site-Specific ADC

AI 导读

ProBio将一款发现阶段肿瘤治疗抗体的全球独家权益授予韩国Dong-A ST子公司AbTis,用于开发位点特异性抗体偶联药物(ADC)。AbTis计划用其AbClick平台推进双特异性ADC管线,ProBio将获得首付款及潜在开发、商业里程碑付款和销售分成。公告未披露金额、抗体靶点及临床前或临床数据。

正文 · 原文

ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.

ProBio, a contract research, development and manufacturing organization, has granted AbTis Co., Ltd. exclusive global rights to a discovery-stage therapeutic antibody directed at an oncology target.¹ AbTis, a South Korean company and subsidiary of Dong-A ST, plans to use the antibody to expand a pipeline of bispecific antibody-drug conjugates (ADCs) built on its site-specific conjugation platform.¹

“This agreement demonstrates the value of ProBio's strategy to not only support our partners' programs, but also generate differentiated assets that can advance into innovative therapeutic development,” said Allen Guo, CEO, ProBio. “By combining ProBio's biologics discovery capabilities with AbTis' site-specific ADC technology, we have the opportunity to accelerate the development of a promising oncology asset and create additional value for patients and our partners.”¹

“This licensing agreement marks an important step in advancing this promising antibody asset toward ADC development,” said Dr. Hyungsuk Choi, CEO, AbTis. “We look forward to leveraging the AbClick platform and working with ProBio to accelerate development of this program.”

What are the terms of the ProBio-AbTis licensing agreement?

AbTis holds the right to develop and commercialize the antibody worldwide.¹ ProBio will receive an upfront payment, with potential developmental and commercial milestone payments and royalties on future sales.¹

The announcement did not disclose payment amounts, name the antibody's target or include preclinical or clinical data on the asset.¹

How does AbTis' AbClick platform conjugate antibodies?

AbTis describes its AbClick platform as enabling controlled, site-specific conjugation, an approach intended to improve ADC consistency compared with conventional nonspecific methods.¹ Peer-reviewed work from AbTis scientists describes one version of the chemistry.

A peptide that binds the antibody's constant region carries a reactive thioester positioned next to a single lysine residue on trastuzumab, allowing that site to be modified selectively.² A subsequent click reaction attached the drug, producing a conjugate with two drugs per antibody that showed activity in cell and animal models.²

That study used an existing antibody as the test case, so it does not speak to the licensed asset.

“This licensing agreement marks an important step in advancing this promising antibody asset toward ADC development,” said Dr. Hyungsuk Choi, CEO, AbTis. “We look forward to leveraging the AbClick platform and working with ProBio to accelerate development of this program.”¹

Why does conjugation consistency matter in ADC development?

A 2025 review notes that conjugation site, drug-to-antibody ratio control and linker stability influence pharmacokinetics, efficacy, and safety.³ The review reports that more than a dozen ADCs have received FDA approval and that more than 200 are in active clinical trials.

It adds that site-specific methods have improved homogeneity and stability, although large-scale manufacturing and regulatory harmonization remain challenges.³ For development and manufacturing organizations, that places the conjugation step within process development and analytical control, not only discovery.

Who is AbTis, and why does the deal matter to manufacturing partners?

AbTis was founded in 2016 and became a Dong-A ST subsidiary in December 2023, when the parent company described AbClick as a third-generation linker platform with medium- to long-term goals of expanding into ADC contract development and manufacturing.⁴ AbTis had previously signed an ADC technology agreement with Lonza.⁴

ProBio offers biotechnology and pharmaceutical partners an integrated path from discovery through development and manufacturing.¹ The licensing agreement links its discovery work to a partner with its own conjugation technology, although the announcement does not say whether ProBio would manufacture the resulting ADC.¹

What are the limitations and next steps?

The asset is at the discovery stage, and no target, binding, efficacy or safety data were provided. The peer-reviewed data cited here involve a single marketed antibody and a two-drug conjugate and do not address bispecific formats.²

Whether the approach delivers consistency and manufacturability at commercial scale will depend on process development and regulatory review of the conjugated product, topics the companies did not address.³ Development timelines, milestone triggers and the antibody's target remain unstated.¹

Sources

  1. ProBio enters exclusive global licensing agreement with AbTis to develop next-generation ADC asset. News release. ProBio Inc. PR Newswire; November 10, 2026. Accessed November 11, 2026.
  2. Lee T, Kim JH, Kwon SJ, et al. Site-selective antibody-drug conjugation by a proximity-driven S to N acyl transfer reaction on a therapeutic antibody. J Med Chem. 2022;65(7):5751-5759. doi:10.1021/acs.jmedchem.2c00084
  3. Alradwan IA, Alnefaie MK, AL Fayez N, et al. Strategic and chemical advances in antibody-drug conjugates. Pharmaceutics. 2025;17(9):1164. doi:10.3390/pharmaceutics17091164
  4. Dong-A ST secures ADC platform with AbTis acquisition. The Asia Business Daily. December 20, 2023. Accessed November 11, 2026.

Related to this article

Beam plans to file the first U.S. application for a base-editing therapy after BEACON met its primary endpoint in sickle cell disease. Credit: Stock.Adobe.com/freshidea

November 11th, 2026

Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.

Read more

After a three-year research collaboration, AstraZeneca has acquired Omniose, whose platform builds conjugate vaccine components inside one E. coli cell. Credit: Stock.Adobe.com/Valeriya Zankovych

November 10th, 2026

AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.

Read more

Efinopegdutide, an investigational GLP-1/glucagon co-agonist, met its 52-week MASH resolution endpoint in a phase 2b trial of 381 treated adults. Credit: Stock.Adobe.com/Formatoriginal

November 10th, 2026

Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.

Read more

Weight loss pills available: Two dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication on a blue background besides a heap of GLP-1 pills. | Image Credit: © Andreas Prott - © Andreas Prott - stock.adobe.com

November 9th, 2026

argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.

Read more

3D illustration of a translucent blue human torso, viewed from the front, with both kidneys highlighted in pink and the rib cage, liver, and intestines faintly visible. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 11th, 2026

ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.

Read more

Close-up photograph of a person using their fingers to hold open a reddened eye while squeezing a drop from a small white-and-blue dropper bottle into it. | Image Credit: © TatjanaMeininger - stock.adobe.com

November 11th, 2026

Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.

Read more

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide

November 10th, 2026

FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.

Read more

FAQ: Sterility Assurance for Injectable Biologics

November 10th, 2026

This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.

Read more

来源:BioPharm International · biopharminternational.com